US's FluMist can now be administered by a healthcare provider or by recipient or caregiver aged 18 or above. India's Nasovac S4 faces hurdles like cost, availability & low acceptance.
MenFive targets 5 causes of meningococcal meningitis, a bacterial infection that can kill within hours. It can cause severe brain damage and sepsis, and is fatal in 50% cases if untreated.
Pune-based SII has got the go-ahead from the Drugs Controller General of India to market the vaccine. Cervical cancer is one of the leading causes of female cancer mortality worldwide.
Cervical cancer in India is the 2nd most frequent cancer among women between 15-44 years of age. Currently, India is fully dependent on foreign manufacturers for the vaccine.
SII's Director of Government and Regulatory Affairs is learnt to have recently communicated to Union Health Ministry that it has a manufactured stock of 24,89,15,000 Covishield doses.
Serum Institute of India, world's largest vaccine manufacturer, will market the nanoparticle protein-based vaccine in Indonesia under the brand name Covovax.
While the Russia-Ukraine war saw the BJP projecting PM Modi as a ‘vishwaguru’ who could end international conflicts, the party has made a nuanced shift in its electoral strategy vis-à-vis the West Asia war.
Report on impact of AI emergence—drawing upon depositions from several ministries—confirms that the developments come in the absence of AI laws or considerations over them.
It’s easy to understand why the government can’t speak the hard truth. When this war ends, as all wars do, India’s interests will lie with both the winner and the loser.
COMMENTS